How a neuroscientist invests in biopharma

How a neuroscientist invests in biopharma

From Capital Ideas Podcast by Capital Group

April 16, 2026 · 26 min

About this episode

Equity analyst Laura Nelson Carney discusses her unique approach to investing in biopharma using her neuroscience background.

Equity analyst Laura Nelson Carney uses her PhD in neuroscience to help spot medical innovation around the world. She brings a deep understanding of science to health care investing, using her research and drug development experience to help identify breakthrough drugs. And today, she's looking beyond biotechs in Boston and San Francisco and turning her attention to China as a growing source of innovation. #CapGroupGlobal This content is intended to highlight issues and be of a general nature. It should not be considered advice, an endorsement or a recommendation. Products mentioned are not an offer of the product and may not be available for sale or purchase in all countries. All investments have risk, and you may lose money. Past results are not a guarantee of future results. Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This content is published by Capital Client Group, Inc., and copyrighted to Capital Group and affiliates, 2026, all rights reserved. For more information, including our detailed disclosures, visit…

People in this episode

Guest: Laura Nelson Carney

Topics covered

  • biopharma
  • medical innovation
  • health care investing
  • neuroscience
  • China
  • drug development

Keywords

  • biopharma
  • neuroscience
  • medical innovation
  • health care
  • drug development
  • China
  • investing

Mentioned in this episode

Organizations: Capital Group

Places: China, Boston, San Francisco

More episodes of Capital Ideas Podcast

Explore listener stats, chart rankings, contacts and more on the Capital Ideas Podcast podcast page.